Jack Humphrey

Jack Humphrey

Auto-generated profile, based on publicly available information

Jack Humphrey

Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York City, NY, USA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 March 2019 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
ACAndrea Cortese
Andrea Cortese
RSRoberto Simone
Roberto Simone
RSRoisin Sullivan
Roisin Sullivan
JVJana Vandrovcova
Jana Vandrovcova
HTHuma Tariq
Huma Tariq
HHHenry Houlden
Henry Houlden

8 October 2018 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
TRTowfique Raj
Towfique Raj
YLYang I. Li
Yang I. Li
GWGarrett Wong
Garrett Wong
JHJack Humphrey
Jack Humphrey
MWMinghui Wang
Minghui Wang
PJPhilip L. De Jager
Philip L. De Jager

2 November 2020 in Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
MPMercedes Prudencio
Mercedes Prudencio
JHJack Humphrey
Jack Humphrey
SPSarah Pickles
Sarah Pickles
ABAnna-Leigh Brown
Anna-Leigh Brown
SHSarah E. Hill
Sarah E. Hill
LPLeonard Petrucelli
Leonard Petrucelli
No treatment for frontotemporal dementia (FTD), the second most common type of early-onset dementia, is available, but therapeutics are being investigated to target the 2 main proteins associated with FTD pathological subtypes: TDP-43 (FTLD-TDP) and tau (FTLD-tau). Testing potential therapies in clinical trials is hampered by our inability to distinguish between patients with FTLD-TDP and FTLD-tau. Therefore, we evaluated truncated stathmin-2 (STMN2) as a proxy of TDP-43 pathology, given the reports that TDP-43 dysfunction causes truncated STMN2 accumulation. Truncated STMN2 accumulated in human induced pluripotent stem cell–derived neurons depleted of TDP-43, but not in those with pathogenic TARDBP mutations in the absence of TDP-43 aggregation or loss of nuclear protein. In RNA-Seq analyses of human brain samples from the NYGC ALS cohort, truncated STMN2 RNA was confined to tissues and disease subtypes marked by TDP-43 inclusions. Last, we validated that truncated STMN2 RNA was elevated in the frontal cortex of a cohort of patients with FTLD-TDP but not in controls or patients with progressive supranuclear palsy, a type of FTLD-tau. Further, in patients with FTLD-TDP, we observed significant associations of truncated STMN2 RNA with phosphorylated TDP-43 levels and an earlier age of disease onset. Overall, our data uncovered truncated STMN2 as a marker for TDP-43 dysfunction in FTD.

1 March 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
YLYang I. Li
Yang I. Li
GWGarrett Wong
Garrett Wong
JHJack Humphrey
Jack Humphrey
TRTowfique Raj
Towfique Raj
Genome-wide association studies (GWAS) have identified over 41 susceptibility loci associated with Parkinson’s Disease (PD) but identifying putative causal genes and the underlying mechanisms remains challenging. Here, we leverage large-scale transcriptomic datasets to prioritize genes that are likely to affect PD by using a transcriptome-wide association study (TWAS) approach. Using this approach, we identify 66 gene associations whose predicted expression or splicing levels in dorsolateral prefrontal cortex (DLFPC) and peripheral monocytes are significantly associated with PD risk. We uncover many novel genes associated with PD but also novel mechanisms for known associations such as MAPT, for which we find that variation in exon 3 splicing explains the common genetic association. Genes identified in our analyses belong to the same or related pathways including lysosomal and innate immune function. Overall, our study provides a strong foundation for further mechanistic studies that will elucidate the molecular drivers of PD.

8 December 2022 in Nature Neuroscience
Verified
Journal Article
Closed access
PDF file
JHJack Humphrey
Jack Humphrey
SVSanan Venkatesh
Sanan Venkatesh
RHRahat Hasan
Rahat Hasan
JHJake T. Herb
Jake T. Herb
KLKatia Lopes
Katia Lopes
TRTowfique Raj
Towfique Raj

26 May 2017 in BMC Medical Genomics
Verified
Journal Article
Open access
PDF file
JHJack Humphrey
Jack Humphrey
WEWarren Emmett
Warren Emmett
PFPietro Fratta
Pietro Fratta
AIAdrian M. Isaacs
Adrian M. Isaacs
VPVincent Plagnol
Vincent Plagnol
Reliable exon recognition is key to the splicing of pre-mRNAs into mature mRNAs. TDP-43 is an RNA-binding protein whose nuclear loss and cytoplasmic aggregation are a hallmark pathology in amyotrophic lateral sclerosis and frontotemporal dementia (ALS/FTD). TDP-43 depletion causes the aberrant inclusion of cryptic exons into a range of transcripts, but their extent, relevance to disease pathogenesis and whether they are caused by other RNA-binding proteins implicated in ALS/FTD are unknown. We developed an analysis pipeline to discover and quantify cryptic exon inclusion and applied it to publicly available human and murine RNA-sequencing data. We detected widespread cryptic splicing in TDP-43 depletion datasets but almost none in another ALS/FTD-linked protein FUS. Sequence motif and iCLIP analysis of cryptic exons demonstrated that they are bound by TDP-43. Unlike the cryptic exons seen in hnRNP C depletion, those repressed by TDP-43 cannot be linked to transposable elements. Cryptic exons are poorly conserved and inclusion overwhelmingly leads to nonsense-mediated decay of the host transcript, with reduced transcript levels observed in differential expression analysis. RNA-protein interaction data on 73 different RNA-binding proteins showed that, in addition to TDP-43, 7 specifically bind TDP-43 linked cryptic exons. This suggests that TDP-43 competes with other splicing factors for binding to cryptic exons and can repress cryptic exon inclusion. Our quantitative analysis pipeline confirms the presence of cryptic exons during the depletion of TDP-43 but not FUS providing new insight into to RNA-processing dysfunction as a cause or consequence in ALS/FTD.